← All trials
NCT05180773
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 27, 2022
- Primary completion
- Aug 30, 2026
- Completion date
- Jan 30, 2027
- First posted
- Jan 6, 2022
- Last posted
- Dec 16, 2022
- Enrollment
- 250
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of PittsburghLead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of PittsburghOverall official - principal investigator
- University of PittsburghSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.